Silexion Therapeutics Corp

For the period ended Jun 30, 2024. Filed Aug 29, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 29, 2024

SLXN$0.11-12.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations (unaudited)

	Six months ended June 30		Three months ended June 30
	2024	2023	2024	2023
U.S. dollars in thousands · U.S. dollars in thousands
OPERATING EXPENSES:
Research and development (including $34 from related party for the six months period ended June 30, 2024 and 2023, respectively, and including $17 from related party for the three months period ended June 30, 2024 and 2023, respectively)	$1,727	$1,916	$766	$1,235
General and administrative (including $24 from related party for the six months period ended June 30, 2024 and 2023, respectively, and including $12 from related party for the three months period ended June 30, 2024 and 2023, respectively)	908	306	619	179
TOTAL OPERATING EXPENSES	2,635	2,222	1,385	1,414
OPERATING LOSS	2,635	2,222	1,385	1,414
Financial expenses, net (including $135 and $0 from related party for the six months period ended June 30, 2024 and 2023, respectively, and including $60 and $0 from related party for the three months period ended June 30, 2024 and 2023, respectively)	270	377	102	452
LOSS BEFORE INCOME TAX	$2,905	$2,599	$1,487	$1,866
INCOME TAX	7	20	2	10
NET LOSS	$2,912	$2,619	$1,489	$1,876
Attributable to:
Equity holders of the Company	2,845	2,427	1,472	1,653
Non-controlling interests	67	192	17	223
	$2,912	$2,619	$1,489	$1,876
LOSS PER SHARE, BASIC AND DILUTED	$11.31	$9.61	$5.87	$6.54
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE	251,655	252,462	250,847	252,462

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE

CONVERTIBLE PREFERRED SHARES AND CAPITAL DEFICIENCY

(U.S. dollars in thousands, except per share data)

Redeemable Convertible Preferred Shares · Total redeemable convertible preferred shares and contingently redeemable
Series A preferred shares · Series A-1 preferred shares · Series A-2 preferred shares · Series A-3 preferred shares · Series A-4 preferred shares · Contingently redeemable non- controlling interests · Ordinary shares · Additional paid-in · Accumulated · Total capital · non- controlling interests, net of capital
Shares · Amount · Shares · Amount · Shares · Amount · Shares · Amount · Shares · Amount · Amount · Shares · Amount · Capital · deficit · deficiency · deficiency
BALANCE AT JANUARY 1, 2023	388,088	$7,307	91,216	$2,392	45,458	$2,264	63,331	$2,683	-	-	$3,586	219,354		$1	$11,203	$(21,869)	$(10,665)	$7,567
CHANGES DURING THE SIX MONTHS PERIOD ENDED JUNE 30, 2023 (unaudited):
Issuance of Preferred A-4 shares, net of issuance cost									21,717	$411					1		1	412
Share-based compensation															64		64	64
Net loss											(192)					(2,427)	(2,427)	(2,619)
BALANCE AS OF JUNE 30, 2023	388,088	$7,307	91,216	$2,392	45,458	$2,264	63,331	$2,683	21,717	$411	$3,394	219,354		$1	$11,268	$(24,296)	$(13,027)	$(5,424)
BALANCE AT JANUARY 1, 2024	388,088	$7,307	91,216	$2,392	45,458	$2,264	63,331	$2,683	21,717	$411	$3,420	219,354		$1	$11,334	$(26,811)	$(15,476)	$3,001
CHANGES DURING THE SIX MONTHS PERIOD ENDED JUNE 30, 2024 (unaudited):
Exercise of options												31,138	**	*	*		*	*
Share-based compensation															64		64	64
Net loss											(67)					(2,845)	(2,845)	(2,912)
BALANCE AS OF JUNE 30, 2024	388,088	$7,307	91,216	$2,392	45,458	$2,264	63,331	$2,683	21,717	$411	$3,353	250,492		$1	$11,398	$(29,656)	$(18,257)	$153

*	Represents an amount less than $1
**	Represents fully vested pre-funded options for the Company’s ordinary shares at an exercise price of $0.01 or 0.01 NIS per share

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE

CONVERTIBLE PREFERRED SHARES AND CAPITAL DEFICIENCY

(U.S. dollars in thousands, except per share data)

Redeemable Convertible Preferred Shares · Total redeemable convertible preferred shares and contingently redeemable
Series A preferred shares · Series A-1 preferred shares · Series A-2 preferred shares · Series A-3 preferred shares · Series A-4 preferred shares · Contingently redeemable non-controlling interests · Ordinary shares · Additional paid-in · Accumulated · Total capital · non- controlling interests, net of capital
	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount	Amount	Shares	Amount	Capital	deficit	deficiency	deficiency
BALANCE AT MARCH 31, 2023	388,088	$7,307	91,216	$2,392	45,458	$2,264	63,331	$2,683	-	-	$3,617	219,354	$1	$11,235	$(22,643)	$(11,407)	$6,856
CHANGES DURING THE THREE MONTHS PERIOD ENDED JUNE 30, 2023 (unaudited):
Issuance of Preferred A-4 shares, net of issuance cost									21,717	$411				1		1	412
Share-based compensation														32		32	32
Net loss											(223)				(1,653)	(1,653)	(1,876)
BALANCE AS OF JUNE 30, 2023	388,088	$7,307	91,216	$2,392	45,458	$2,264	63,331	$2,683	21,717	$411	3,394	219,354	$1	$11,268	$(24,296)	$(13,027)	$(5,424)
BALANCE AT MARCH 31, 2024	388,088	$7,307	91,216	$2,392	45,458	$2,264	63,331	$2,683	21,717	$411	$3,370	250,492	$1	$11,366	$(28,184)	$(16,817)	$1,610
CHANGES DURING THE THREE MONTHS PERIOD ENDED JUNE 30, 2024 (unaudited):
Share-based compensation														32		32	32
Net loss											(17)				(1,472)	(1,472)	(1,489)
BALANCE AS OF JUNE 30, 2024	388,088	$7,307	91,216	$2,392	45,458	$2,264	63,331	$2,683	21,717	$411	$3,353	250,492	$1	$11,398	$(29,656)	$(18,257)	$153

*	Represents an amount less than $1

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.